Wendy L. Allen
Belfast, NIR BT97BL, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The pseudo-caspase FLIP(L) regulates cell fate following p53 activation.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 15, 2020
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer.
Journal: Molecular cancer therapeutics
Published: July 30, 2017
Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 08, 2016
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
Journal: Cancer immunology research
Published: December 14, 2015
A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer.
Journal: Frontiers in oncology
Published: August 28, 2013
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 04, 2012
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Journal: Molecular cancer therapeutics
Published: June 06, 2012
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Journal: Molecular cancer therapeutics
Published: October 27, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026